175 related articles for article (PubMed ID: 8382971)
1. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties.
Berg DT; Burck PJ; Berg DH; Grinnell BW
Blood; 1993 Mar; 81(5):1312-22. PubMed ID: 8382971
[TBL] [Abstract][Full Text] [Related]
2. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
3. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
Rydzewski A; Castellino FJ
Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682
[TBL] [Abstract][Full Text] [Related]
4. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
[TBL] [Abstract][Full Text] [Related]
5. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L
J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513
[TBL] [Abstract][Full Text] [Related]
7. The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin.
Nesheim M; Fredenburgh JC; Larsen GR
J Biol Chem; 1990 Dec; 265(35):21541-8. PubMed ID: 2123871
[TBL] [Abstract][Full Text] [Related]
8. Interactions between the finger and kringle-2 domains of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Kaneko M; Sakata Y; Matsuda M; Mimuro J
J Biochem; 1992 Feb; 111(2):244-8. PubMed ID: 1314812
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue-type plasminogen activator.
Wojta J; Beckmann R; Turcu L; Wagner OF; van Zonneveld AJ; Binder BR
J Biol Chem; 1989 May; 264(14):7957-61. PubMed ID: 2470738
[TBL] [Abstract][Full Text] [Related]
10. Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.
Wilhelm OG; Jaskunas SR; Vlahos CJ; Bang NU
J Biol Chem; 1990 Aug; 265(24):14606-11. PubMed ID: 2117612
[TBL] [Abstract][Full Text] [Related]
11. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
[TBL] [Abstract][Full Text] [Related]
12. Kringle 1 domain of human tissue-type plasminogen activator is a functional module mediating fibrinogen-stimulated plasminogenolytic activity.
Stern A; Weidle UH
Gene; 1990 Mar; 87(2):305-8. PubMed ID: 2158930
[TBL] [Abstract][Full Text] [Related]
13. Tissue-type plasminogen activator mutants imitating urokinase in the peptide link between kringle and protease domains and at selected sites within the protease domain.
Hinzmann B; Wernicke D; Pfeifer M; Zacharias U; Fischer B; Eisenmenger F; Will H
Eur J Biochem; 1993 Apr; 213(1):437-43. PubMed ID: 8386628
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
[TBL] [Abstract][Full Text] [Related]
15. The activation of type 1 and type 2 plasminogen by type I and type II tissue plasminogen activator.
Mori K; Dwek RA; Downing AK; Opdenakker G; Rudd PM
J Biol Chem; 1995 Feb; 270(7):3261-7. PubMed ID: 7852411
[TBL] [Abstract][Full Text] [Related]
16. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
Boutaud A; Castellino FJ
Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
[TBL] [Abstract][Full Text] [Related]
17. Functional effects of kringle 2 glycosylation in a hybrid plasminogen activator.
Asselbergs FA; Bürgi R; van Oostrum J
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):27-33. PubMed ID: 8384498
[TBL] [Abstract][Full Text] [Related]
18. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.
Novokhatny V; Medved L; Lijnen HR; Ingham K
J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771
[TBL] [Abstract][Full Text] [Related]
19. High resolution analysis of functional determinants on human tissue-type plasminogen activator.
Bennett WF; Paoni NF; Keyt BA; Botstein D; Jones AJ; Presta L; Wurm FM; Zoller MJ
J Biol Chem; 1991 Mar; 266(8):5191-201. PubMed ID: 1900516
[TBL] [Abstract][Full Text] [Related]
20. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains.
Larsen GR; Henson K; Blue Y
J Biol Chem; 1988 Jan; 263(2):1023-9. PubMed ID: 3121618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]